Effect of combined therapy by pinaverium bromide and itopride hydrochloride on clinical semiology and quality of life of patients with combination of constipation variant of irritable bowel syndrome and functional dyspepsia
Abstract
Aim of investigation. To estimate the effect of combined treatment by pinaverium bromide and itopride hydrochloride on clinical semiology and quality of life of patients with combination of constipation-predominant variant of irritable bowel syndrome (IBS-C) with postprandial distress syndrome (PDS).
Material and methods. Overall 49 patients with IBS-C (Rome criteria III) were investigated, 31 of them also had accompanying PDS (Rome criteria III). Fourteen patients with combination of IBS-C and PDS (group I) for 4 wks received combined treatment by pinaverium bromide and itopride hydrochloride. Monotherapy by pinaverium bromide for 4 wks was carried out in 17 patients with combination of IBS-C and PDS (group II) and 18 patients with IBS-C (group III). Both symptoms and parameters of quality of life (SF-36) were estimated prior to onset of treatment and in 4 wks after its termination.
Results. Combined therapy by pinaverium bromide and itopride hydrochloride for 4 wks in comparison to monotherapy by pinaverium bromide promoted more prominent reduction of abdominal pain intensity (p<0,001), meteorism (p<0,001), epigastric heaviness (p<0,001), complete disappearance of nausea and belching in many patients with combination of IBS-C and PDS. Treatment by pinaverium bromide in combination with itopride hydrochloride was characterized by absence of serious side effects and resulted in significant improvement of quality of life (p<0,001).
Conclusions. Application of the combined therapy including spasmolytic drug pinaverium bromide and prokinetic agent itopride hydrochloride for patients combination of IBS-C and PDS significantly increased efficacy of relief of clinical symptoms of combined disease and improved quality of life of patients.
About the Authors
O. V. Krapivnaya
Non-state healthcare institution «Khabarovsk-1 station railway clinical hospital» JSC «Russian Railways»
Russian Federation
Russian Federation
Krapivnaya Oksana V. — MD, head of gastroenterological department
680022, Khabarovsk, Voronezhskaya street, 49
S. A. Alekseyenko
State educational government-financed institution of higher professional education «Far East state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Alekseyenko Sergey A. — MD, PhD, professor, head of the chair of hospital course of internal diseases
680000, Khabarovsk, Murav’yev-Amursky street, 35
References
1. Suzuki H., Hibi T. Overlap syndrome of functional dyspepsia and irritable bowel syndrome — are both diseases mutually exclusive? J Neurogastroenterol Motil 2011; 17(4):360-5.
2. Wang A., Liao X., Xiong L., Peng S., Xiao Y., Liu S., Hu P., Chen M. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol 2008; 8:43.
3. Talley N. J., Dennis E. H., Schettler-Duncan V.A., Lacy B. E., Olden K. W., Crowell M. D. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98:2454-9.
4. Matsuzaki J., Suzuki H., Asakura K., Fukushima Y., Inadomi J. M., Takebayashi T., Hibi T. Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterol Motil 2012; 24(4):325e164.
5. Ивашкин В.Т, Полуэктова Е. А. О сочетании синдрома функциональной диспепсии и синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2011; 21(4):75-81.
6. Huang X., Lv B., Zhang S., Fan Y. H., Meng L. N. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol 2012; 18(48):7371-7.
7. Longstreth G. F., Thompson W. G., Chey W. D., Houghton L. A., Mearin F., Spiller R. C. Functional bowel disorders. Gastroenterology 2006; 130(5):1480-91.
8. Ruepert L., Quartero A. O., de Wit N. J., van der Heijden G. J., Rubin G., Muris J. W. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. The Cochraine Library 2013, Issue 3.
9. Tack J., Talley N. J., Camilleri M., Holtmann G., Hu P., Malagelada J. R., Stanghellini V. Functional gastroduodenal disorders. Gastroenterology 2006; 130(5):1466-79.
10. Perveen I., Rahman M. M., Saha M., Rahman M. M., Hasan M. Q. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol 2014; 33(3):265-73.
11. Клинические рекомендации Российской гастроэнтерологической ассоциации, Ассоциации колопроктологов России по диагностике и лечению больных с синдромом раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2014; 24(2):92-102.
12. Маев И. В., Самсонов А. А., Андреев Д. Н. Клиническое значение синдрома «перекреста» функциональной диспепсии и гастроэзофагеальной рефлюксной болезни. Клин перспективы гастроэнтерол гепатол 2013; 5:17-22.
13. Ивашкин В. Т., Шептулин А. А., Трухманов А. С. Клинические аспекты функциональной диспепсии и эффективность ганатона (итоприда гидрохлорида) в ее лечении. Рос журн гастроэнтерол гепатол колопроктол 2009; 19(6):17-22.
Review
For citations:
Krapivnaya O.V., Alekseyenko S.A. Effect of combined therapy by pinaverium bromide and itopride hydrochloride on clinical semiology and quality of life of patients with combination of constipation variant of irritable bowel syndrome and functional dyspepsia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(2):22-27. (In Russ.)
Views:
143
Email this article 
